Overview

Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 486757 in subjects with chronic cough. Subjects will be randomized to receive SCH 486757 or placebo for 14 days. After a 2-week washout period, subjects will be crossed over to the other treatment. The primary objective is to evaluate the effectiveness of SCH 486757 in reducing cough reflex sensitivity as determined by a challenge with capsaicin, an agent that induces cough.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.